Schulman IRB's Michele Russell-Einhorn Named to 2017 PharmaVOICE 100 Most Inspiring People

12:03 EDT 1 Aug 2017 | PR Newswire

CINCINNATI and DURHAM, N.C., Aug. 1, 2017 /PRNewswire/ -- Michele Russell-Einhorn, JD, Vice President of Human Research Protection Services and Institutional Official at Schulman IRB, the industry-leading central IRB in customer service and technology, was named to the 2017 PharmaVOICE 100 Most Inspiring People list.

PharmaVOICE's 100 Most Inspiring People list recognizes individuals in the life sciences industry for their inspirational qualities and ability to view industry trends as opportunities instead of obstacles; their passion and conviction for the industry; their ability to innovate and think outside of the box and develop breakthrough strategies, products, and services; for pioneering new paths and lifting their companies to new heights; for taking the time to mentor and guide the next generation of industry leaders; and for their dedication to improving the lives of patients.

"Michele being named as one of the 100 most inspiring people in the industry should come as no surprise to those who know her," said Michael Woods, President and CEO, Schulman IRB. "Michele's energy and passion for improving research efficiencies and human subject protections makes her a well deserving honoree of this prestigious distinction."

Russell-Einhorn joined Schulman in September 2016 and oversaw the development of Schulman's Central Oncology Review (COR) division. She also currently serves as co-chair of the Subpart A Subcommittee of the US Department of Health and Human Services (DHHS) Secretary's Advisory Committee on Human Research Protections (SACHRP) and is a site visitor for the Association for the Accreditation of Human Research Protection Programs (AAHRPP). Prior to her position at Schulman, Russell-Einhorn served as Senior Director of Dana-Farber Cancer Institute's Office for Human Research Studies.

About Schulman IRB

Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services in clinical quality assurance (CQA) and human research protections (HRP), and it also offers a commercial institutional biosafety committee (IBC) service. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).

For more information, please visit or follow @SchulmanIRB on Twitter or on LinkedIn.

View original content with multimedia:



More From BioPortfolio on "Schulman IRB's Michele Russell-Einhorn Named to 2017 PharmaVOICE 100 Most Inspiring People"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...